Investigation Report on China's Repaglinide Market, 2018-2022
Description
Since the 1980s, China’s economic development has improved living standards and urbanization level, which significantly increases the incidence of obesity, diabetes and other non-communicable diseases in China. And population aging and other factors sharply raise the incidence of type 2 diabetes. The number of type 2 diabetic patients in China surpassed 110 million at the end of 2017, and is growing by 1.5 million to 2 million every year.
Insulin secretagogues are mainly used to treat type 2 diabetes. Compared with sulfonylureas, insulin secretagogues have short-lasting effects and cause few hypoglycemia reactions.
Developed by Danish company Novo Nordisk and German company Boehringer Ingelheim, Repaglinide is a non-sulfonylurea-based insulin secretagogue used to control postprandial hyperglycemia. The drug was launched in the U.S. in Apr.1998. Entering China in 2000, Novo Nordisk's NovoNorm has few competitors. According to CRI's market research, by sales value, the market share of Novo Nordisk was about 80% in 2017, while the market share of Jiangsu Hansoh Pharmaceutical Co., Ltd., its major competitor, was less than 20%. But Novo Nordisk’s market share is sliding because NovoNorm is more expensive than China-made generic drugs. In 2017, the sales value of Repaglinide was about CNY 272 million in China, representing a slow decline from 2013 to 2017. Considering good efficacy, reasonable prices, and the increasing number of type 2 diabetic patients, Repaglinide will still have certain growth potential in China in the next few years.
Topics Covered:
Since the 1980s, China’s economic development has improved living standards and urbanization level, which significantly increases the incidence of obesity, diabetes and other non-communicable diseases in China. And population aging and other factors sharply raise the incidence of type 2 diabetes. The number of type 2 diabetic patients in China surpassed 110 million at the end of 2017, and is growing by 1.5 million to 2 million every year.
Insulin secretagogues are mainly used to treat type 2 diabetes. Compared with sulfonylureas, insulin secretagogues have short-lasting effects and cause few hypoglycemia reactions.
Developed by Danish company Novo Nordisk and German company Boehringer Ingelheim, Repaglinide is a non-sulfonylurea-based insulin secretagogue used to control postprandial hyperglycemia. The drug was launched in the U.S. in Apr.1998. Entering China in 2000, Novo Nordisk's NovoNorm has few competitors. According to CRI's market research, by sales value, the market share of Novo Nordisk was about 80% in 2017, while the market share of Jiangsu Hansoh Pharmaceutical Co., Ltd., its major competitor, was less than 20%. But Novo Nordisk’s market share is sliding because NovoNorm is more expensive than China-made generic drugs. In 2017, the sales value of Repaglinide was about CNY 272 million in China, representing a slow decline from 2013 to 2017. Considering good efficacy, reasonable prices, and the increasing number of type 2 diabetic patients, Repaglinide will still have certain growth potential in China in the next few years.
Topics Covered:
- Situation of type 2 diabetes in China
- Size of China's Repaglinide market
- Major Repaglinide manufacturers in China
- Competition on China's Repaglinide market
- Retail prices of Repaglinide in China
- Prospect of China's Repaglinide market from 2018 to 2022
1 RELEVANT CONCEPTS OF REPAGLINIDE
1.1 Indications for Repaglinide
1.2 Development of Repaglinide in China
1.3 Governmental Approval of Repaglinide in China
2 SALES OF REPAGLINIDE IN CHINA, 2013-2017
2.1 Sales Value of Repaglinide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Repaglinide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Repaglinide by Dosage Form in China, 2013-2017
3 MAJOR REPAGLINIDE MANUFACTURERS IN CHINA, 2013-2017
3.1 Analysis on Market Share of Major Repaglinide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Novo Nordisk
3.2.1 Enterprise Profile
3.2.2 Sales of Novo Nordisk's Repaglinide in China
3.3 Jiangsu Hansoh Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide in China
3.4 Tianjin Kangrui Pharmaceutical Co., Ltd.
3.5 Beijing Beilu Pharmaceutical Co., Ltd.
3.6 Beijing Winsunny Pharmaceutical Co., Ltd.
4 PRICES OF REPAGLINIDE IN CHINA, 2017-2018
4.1 Novo Nordisk (NovoNorm)
4.2 Jiangsu Hansoh Pharmaceutical Co., Ltd. (Fulaidi)
4.3 Tianjin Kangrui Pharmaceutical Co., Ltd. (Tianhu)
4.4 Beijing Beilu Pharmaceutical Co., Ltd. (Ruiliean)
4.5 Beijing Winsunny Pharmaceutical Co., Ltd. (Wansheng Liping)
5 PROSPECT OF CHINA'S REPAGLINIDE MARKET, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
1.1 Indications for Repaglinide
1.2 Development of Repaglinide in China
1.3 Governmental Approval of Repaglinide in China
2 SALES OF REPAGLINIDE IN CHINA, 2013-2017
2.1 Sales Value of Repaglinide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Repaglinide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Repaglinide by Dosage Form in China, 2013-2017
3 MAJOR REPAGLINIDE MANUFACTURERS IN CHINA, 2013-2017
3.1 Analysis on Market Share of Major Repaglinide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Novo Nordisk
3.2.1 Enterprise Profile
3.2.2 Sales of Novo Nordisk's Repaglinide in China
3.3 Jiangsu Hansoh Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide in China
3.4 Tianjin Kangrui Pharmaceutical Co., Ltd.
3.5 Beijing Beilu Pharmaceutical Co., Ltd.
3.6 Beijing Winsunny Pharmaceutical Co., Ltd.
4 PRICES OF REPAGLINIDE IN CHINA, 2017-2018
4.1 Novo Nordisk (NovoNorm)
4.2 Jiangsu Hansoh Pharmaceutical Co., Ltd. (Fulaidi)
4.3 Tianjin Kangrui Pharmaceutical Co., Ltd. (Tianhu)
4.4 Beijing Beilu Pharmaceutical Co., Ltd. (Ruiliean)
4.5 Beijing Winsunny Pharmaceutical Co., Ltd. (Wansheng Liping)
5 PROSPECT OF CHINA'S REPAGLINIDE MARKET, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
SELECTED CHARTS
Chart Sales Value of Repaglinide in China, 2013-2017
Chart Sales Value of Repaglinide in Parts of China, 2013-2017
Chart Sales Volume of Repaglinide in China, 2013-2017
Chart Sales Volume of Repaglinide in Parts of China, 2013-2017
Chart Market Share of Top 5 Repaglinide Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Repaglinide Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of Novo Nordisk's Repaglinide in China, 2013-2017
Chart Sales Volume of Novo Nordisk's Repaglinide in China, 2013-2017
Chart Sales Value of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Volume of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Tianjin Kangrui Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Beijing Beilu Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Beijing Winsunny Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Prices of Novo Nordisk's Repaglinide in Parts of China, 2017-2018
Chart Prices of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide in Parts of China, 2017-2018
Chart Prices of Tianjin Kangrui Pharmaceutical Co., Ltd.'s Repaglinide in Parts of China, 2017-2018
Chart Forecast on Sales Value of Repaglinide in China, 2018-2012
Chart Sales Value of Repaglinide in China, 2013-2017
Chart Sales Value of Repaglinide in Parts of China, 2013-2017
Chart Sales Volume of Repaglinide in China, 2013-2017
Chart Sales Volume of Repaglinide in Parts of China, 2013-2017
Chart Market Share of Top 5 Repaglinide Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Repaglinide Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of Novo Nordisk's Repaglinide in China, 2013-2017
Chart Sales Volume of Novo Nordisk's Repaglinide in China, 2013-2017
Chart Sales Value of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Volume of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Tianjin Kangrui Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Beijing Beilu Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Sales Value of Beijing Winsunny Pharmaceutical Co., Ltd.'s Repaglinide, 2013-2017
Chart Prices of Novo Nordisk's Repaglinide in Parts of China, 2017-2018
Chart Prices of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s Repaglinide in Parts of China, 2017-2018
Chart Prices of Tianjin Kangrui Pharmaceutical Co., Ltd.'s Repaglinide in Parts of China, 2017-2018
Chart Forecast on Sales Value of Repaglinide in China, 2018-2012
